ESMC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ESMC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Escalon Medical's revenue per share for the three months ended in Sep. 2024 was $0.38. Escalon Medical's revenue per share for the trailing twelve months (TTM) ended in Sep. 2024 was $1.59.
Warning Sign:
Escalon Medical Corp revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Escalon Medical was 24.10% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 4.60% per year. During the past 5 years, the average Revenue Per Share Growth Rate was -1.40% per year. During the past 10 years, the average Revenue Per Share Growth Rate was -4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Escalon Medical's Revenue per Share or its related term are showing as below:
During the past 13 years, Escalon Medical's highest 3-Year average Revenue Per Share Growth Rate was 179.40% per year. The lowest was -68.20% per year. And the median was -0.70% per year.
The historical data trend for Escalon Medical's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Escalon Medical Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
Revenue per Share | Get a 7-Day Free Trial | 1.27 | 1.41 | 0.81 | 0.90 | 1.62 |
Escalon Medical Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Revenue per Share | Get a 7-Day Free Trial | 0.40 | 0.39 | 0.36 | 0.47 | 0.38 |
For the Medical Devices subindustry, Escalon Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Escalon Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Escalon Medical's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Escalon Medical's Revenue Per Share for the fiscal year that ended in Jun. 2024 is calculated as
Revenue Per Share (A: Jun. 2024 ) | = | Revenue (A: Jun. 2024 ) | / | Shares Outstanding (Diluted Average) (A: Jun. 2024 ) |
= | 11.982 | / | 7.415 | |
= | 1.62 |
Escalon Medical's Revenue Per Share for the quarter that ended in Sep. 2024 is calculated as
Revenue Per Share (Q: Sep. 2024 ) | = | Revenue (Q: Sep. 2024 ) | / | Shares Outstanding (Diluted Average) (Q: Sep. 2024 ) |
= | 2.781 | / | 7.415 | |
= | 0.38 |
Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Escalon Medical (OTCPK:ESMC) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Escalon Medical's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
David James Jacovini | director | 120 PINE STREET, PHILADELPHIA PA 19106 |
John Dogum | director | 1818 MARKET STREET, 35TH FLOOR, PHILADELPHIA PA 19103 |
Richard J Depiano | director | 435 DEVON PARK DRIVE, SUITE 100, WAYNE PA 19087 |
Lisa A Napolitano | director | 351 EAST CONESTOGA ROAD, WAYNE PA 19087 |
C Sean Closkey | director | 1700 MARKET STREET, 19TH FLOOR, PHILADELPHIA PA 19103 |
C Todd Trusk | director | 1410 RUSSELL ROAD, SUITE 100, WAYNE PA 19301 |
Robert Michael O'connor | officer: Chief Financial Officer | 53 SORREL RUN, MT. LAUREL NJ 08054 |
Anthony J Coppola | director | 1 NORTH NEW YORK ROAD, SMITHVILLE NJ 08205 |
Federman Jay L Md | director | 501 N. ESSEX AVENUE, NARBERTH PA 19072 |
Kwan William L G | director | 351 EAST CONESTOGA ROAD, WAYNE PA 19087 |
Mark Wallace | officer: Chief Operating Officer | 565 E SWEDESFORD ROAD, STE 200, WAYNE PA 19087 |
Fred G Choate | director | 601 DELSEA DRIVE, WASHINGTON TOWNSHIP NJ 08080 |
Depiano Richard J Jr | officer: President | 575 E. SWEDESFORD ROAD, SUITE 100, WAYNE PA 19087 |
Berkowitz David | officer: Principal Accounting Officer | 565 EAST SWEDESFORD ROAD, SUITE 200, WAYNE PA 19087 |
Mark H Karsch | officer: CFO | 565 EAST SWEDESFORD ROAD, SUITE 200, WAYNE PA 19087 |
From GuruFocus
By gurufocus • 05-15-2009
By gurufocus 10qk • 05-20-2010
By gurufocus 10qk • 11-16-2009
By gurufocus 10qk • 10-12-2010
By gurufocus 10qk • 11-15-2010
By gurufocus • 02-18-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.